Results 381 to 390 of about 540,232 (408)
Some of the next articles are maybe not open access.
Tacrolimus in hematopoietic stem cell transplantation
Expert Opinion on Drug Metabolism & Toxicology, 2009Graft-versus-host disease (GVHD) associated with allogeneic peripheral blood or marrow transplantation is a serious life-threatening complication. Most of the available literature support the use of tacrolimus as a prophylactic agent for acute GVHD.To review the pharmacology, efficacy and safety of tacrolimus and recommend its place in therapy for the ...
Daniel R. Couriel, Kara Fortune
openaire +3 more sources
Hematopoietic Stem Cell Transplantation
2018Introduced in the early 1970s for treatment of aplastic anemia and leukemia, hematopoietic cell transplantation (HCT) offers treatment for a growing number of patients with complex hematologic malignancies, dysfunctional or absent immune systems, inherited or acquired marrow failure, and selected genetic disorders including hemoglobinopathies and ...
Natia Esiashvili, Michael A. Pulsipher
openaire +3 more sources
Hematopoietic Stem Cell Transplantation for Osteopetrosis
Pediatric Clinics of North America, 2010Osteopetrosis is the generic name for a group of diseases caused by deficient formation or function of osteoclasts, inherited in either autosomal recessive or dominant fashion. Osteopetrosis varies in severity from a disease that may kill infants to an incidental radiological finding in adults.
openaire +3 more sources
Hematopoietic Stem Cell Transplantation
2005Publisher Summary This chapter deals with different aspects related to Hematopoietic stem cell transplantation (HSCT). It has become an accepted therapeutic modality for a wide variety of diseases and is increasingly utilized for the treatment of malignant and nonmalignant disorders.
openaire +2 more sources
Hematopoietic Stem Cell Transplantation in Children
Critical Care Nursing Clinics of North America, 2011Medical and nursing care of the hematopoietic stem cell transplantation (HSCT) recipient are complex because of the pathophysiology, HSCT process, pre-HSCT conditioning regimens, numerous medications and therapies, acute and chronic complications, adverse effects, resources involved, and environmental considerations.
Julie A. Kolins +3 more
openaire +3 more sources
Hematopoietic stem cell transplantation
Hématologie, 2017Suite a la decouverte du systeme HLA (human leucocyte antigen) par Jean Dausset en 1958, la greffe de cellules souches hematopoietiques a progressivement montre son pouvoir therapeutique dans la prise en charge des hemopathies malignes mais aussi benignes.
Jean-Edouard Martin +2 more
openaire +2 more sources
Hematopoietic Stem Cell Transplantation
2015Hematopoietic stem cell transplant (HSCT) is increasingly used for the treatment of both malignancies and nonmalignant diseases. This has been made possible by several factors, including expansion of the unrelated donor pool, advances in mobilization and collection of autologous cells, and reduced intensity conditioning regimens.
Sogol Mostoufi-Moab +2 more
openaire +2 more sources
Mouse Hematopoietic Stem Cell Transplantation
2013Hematopoietic stem cells (HSCs) are capable of self-renewal and multi-lineage reconstitution of hematopoiesis in irradiated transplant recipient mice. As such, bone marrow transplantation (BMT) is a major assay commonly used to examine murine HSC activity.
Paulina H. Liang, Hui Cheng, Tao Cheng
openaire +3 more sources
Hematopoietic Stem Cell Transplant [PDF]
, 2015 Children treated with hematopoietic stem cell transplantation (HSCT), particularly allogeneic HSCT, are at particular risk for late effects of therapy. Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity in these survivors. In addition, the source of stem cells and the transplant conditioning regimen (which may include both ...
Adam Gassas +2 more
openaire +1 more source
Hematopoietic Stem Cell Transplant
2013Hematopoietic stem cell transplant (HSCT) is a treatment option in many otherwise deadly conditions, but its development is a great challenge in limited resourced countries. These countries represent a heterogeneous group with widely different problems, so each new HSCT program must develop its own project on its particular settings.
Cristián Sotomayor, Julia Palma
openaire +2 more sources